Improve Medical Instruments (SZSE:300030 Shareholders Incur Further Losses as Stock Declines 16% This Week, Taking Three-year Losses to 29%
Improve Medical Instruments (SZSE:300030 Shareholders Incur Further Losses as Stock Declines 16% This Week, Taking Three-year Losses to 29%
It is doubtless a positive to see that the Improve Medical Instruments Co., Ltd. (SZSE:300030) share price has gained some 91% in the last three months. But that cannot eclipse the less-than-impressive returns over the last three years. In fact, the share price is down 29% in the last three years, falling well short of the market return.
看到阳普医疗股份有限公司(SZSE:300030)股价在过去三个月内上涨了约91%,无疑是一个积极的迹象。但这并不能掩盖过去三年里不那么令人印象深刻的回报。实际上,股价在过去三年里下跌了29%,远低于市场回报。
After losing 16% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
在过去的一周中下跌16%之后,值得调查公司的基本面,以了解从过去的表现中可以推断出什么。
Because Improve Medical Instruments made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.
由于阳普医疗上个十二个月亏损,我们认为市场目前可能更关注营收和营收增长。通常情况下,无盈利公司的股东通常希望看到强劲的营收增长。有些公司愿意延迟盈利以加快营收增长,但在这种情况下,人们会希望出色的收入增长来弥补缺乏盈利的情况。
Over the last three years, Improve Medical Instruments' revenue dropped 13% per year. That is not a good result. The stock has disappointed holders over the last three years, falling 9%, annualized. That makes sense given the lack of either profits or revenue growth. Of course, sentiment could become too negative, and the company may actually be making progress to profitability.
在过去三年里,阳普医疗收入每年下降13%。这不是一个好结果。股票在过去三年里令持有者失望,年化下跌9%。鉴于缺乏盈利或营收增长,这是可以理解的。当然,情绪可能变得太负面,公司实际上可能正在朝着盈利方向取得进展。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以看到以下收益和营收的变化情况(通过单击图像了解精确值)。

Take a more thorough look at Improve Medical Instruments' financial health with this free report on its balance sheet.
使用这份免费报告,详细了解阳普医疗的财务状况。
A Different Perspective
不同的观点
We regret to report that Improve Medical Instruments shareholders are down 13% for the year. Unfortunately, that's worse than the broader market decline of 0.6%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 1.9% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Improve Medical Instruments better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Improve Medical Instruments you should know about.
遗憾地通报,阳普医疗的股东今年下跌了13%。不幸的是,这比整体市场下跌0.6%更糟。话虽如此,在下跌市场中一些股票被过度抛售是不可避免的。关键是保持关注基本发展情况。 然而,长期股东已赚到钱,过去五年每年增长1.9%。最近的抛售可能是一个机会,值得检查基本数据,寻找长期增长趋势的迹象。 跟踪股价表现长期来看总是很有趣。但要更好地了解阳普医疗,我们需要考虑许多其他因素。 比如,要考虑风险。每家公司都有风险,我们已经发现了阳普医疗的2个警示信号,您应该知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
当然,您可能在其他地方找到一家出色的企业进行投资。因此,请查看我们预计将实现盈利增长的公司的免费列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。